pancreatic cancer

  •  
  •  

    Rankings of Most Common and Deadly Cancer Types Will Shift Over Next Two Decades

    In the next two decades, rankings of incidence and death across cancer types will undergo important changes in the U.S., according to new research led by Lola Rahib, PhD, Director of Scientific and Clinical Affairs at Cancer Commons, as well as the Pancreatic Cancer Action Network (PanCAN) in collaboration with The University of Texas MD Anderson Cancer Center. Published today in JAMA Network Open,… Read more »

  •   George Lundberg, MD

    Article from the Miami Herald curated by Contributing Editor George Lundberg, MD, who notes: 

    The RenovoCath chemotherapy device permits targeted delivery of usual chemotherapy drugs directly into, and limited to, localized but inoperable pancreatic cancers. It is currently being tested in a phase 3 clinical trial.

    .

  •  

    Pancreatic Cancer Survival Rates: What Do They Really Mean?

    Lola Rahib, PhD

    The American Cancer Society estimates that in 2020, 57,600 people in the U.S. will be diagnosed with pancreatic cancer and 47,050 will die from the disease. But not everyone’s pancreatic cancer is the same. Understanding what survival rates mean—and which factors can impact them—could help you navigate your or your loved one’s disease. What is the five-year relative survival rate for pancreatic cancer? In… Read more »

  •   George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    Molecularly matched treatment for pancreatic cancer may extend life for some patients.

    Go to full article published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from WebMD curated by Editor in Chief George Lundberg, MD, who notes: 

    An aggressive 3-part approach may offer hope for some patients with stage 4 pancreatic cancer.

    Go to full article published by WebMD.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •  

    Using Real World Evidence to Show Initial Results of a Drug Combination in Pancreatic Cancer Patients

    Lola Rahib, PhD

    In collaboration with xCures and the Huntsman Cancer Institute at the University of Utah, Cancer Commons presented initial findings from our real-world data registry on a novel treatment combination for pancreatic cancer patients at a conference in San Diego, CA, today. The “Special Conference on Advancing Precision Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies” is hosted by the… Read more »

  •  
  •   George Lundberg, MD

    Research paper from The Journal of the American Medical Association (JAMA) curated by Editor in Chief George Lundberg, MD, who notes: 

    The U.S. Preventive Services Task Force recommends against screening for pancreatic cancer in asymptomatic adults.

    Go to full paper published in JAMA.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD:

    The pancreas is made up of three main cellular components: glands, ducts, and hormone-producing cells, some of which are known as neuroendocrine cells. All can develop malignant tumors, with very different characteristics.

    To learn more about pancreatic neuroendocrine tumors, which begin in neuroendocrine cells in the pancreas, check out this comprehensive, authoritative, detailed, up-to-date, unbiased overview from Medscape. (Free registration may be required to view the content.)